Vaccitech KOL Webinar: Status of Tolerogenic Immunotherapies for Celiac Disease and Other Autoimmune Diseases with a Focus on VTP-1000

Join us for a virtual KOL Event with Vaccitech, featuring Robert Anderson, MD, PhD (Novoviah Pharmaceuticals, Brisbane, Australia) and Professor Christopher Jewell, PhD (University of Maryland) who will discuss the unmet needs and the current status of treatments for celiac disease and other autoimmunity indications, along with the potential for tolerogenic immunotherapies in the current treatment landscape.

The event will highlight nanoparticle technologies, including Vaccitech’s SNAPvax platform for immunotherapies to induce tolerance, with a review of the latest supporting data. The Vaccitech leadership team will present on its preclinical asset VTP-1000 for treating celiac disease and provide an overview of the SNAPvax platform that underlies VTP-1000 and its potential for targeting other autoimmune disease indications, along with a company update and insight into its future directions.

A live Q&A session will follow the formal presentations.

The post Vaccitech KOL Webinar: Status of Tolerogenic Immunotherapies for Celiac Disease and Other Autoimmune Diseases with a Focus on VTP-1000 appeared first on LifeSci Events.